Drug Trial Radar · NCT07465913
Rocklatan vs Latanoprost Post-DSLT
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
May 14, 2026
Primary completion
May 6, 2027
Study completion May 6, 2027
Sponsor
- Lead sponsor
- Eye Centers of Southeast TexasAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sengi
- First posted
- Mar 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-masked, single-site, prospective, contralateral eye study designed to evaluate the outcomes of Direct Selective Laser Trabeculoplasty (DSLT) followed by the addition of combination netarsudil and latanoprost (Rocklatan) versus latanoprost monotherapy. The study will be conducted at one investigational site. The primary endpoint is the change in mean diurnal intraocular pressure (IOP) from baseline (post DSLT and post washout) at visit 3 between the two groups. Secondary endpoints include the change in mean IOP from baseline at each timepoint (8am, 12pm, 4pm) at visit 3 between groups, and the mean percentage decrease in IOP from baseline for each group. Assessments will be conducted at three key visits: Visit 1 (Screening Phase and DSLT Procedure on Day 0), Visit 2 (Baseline Visit post washout at Week 8), and Visit 3 (Follow-Up Visit 1 at Week 12). Each visit will include specific examinations and measurements such as visual field and OCT imaging, diurnal IOP measurements, and documentation of adverse events.
Conditions
- Glaucoma
Interventions
Rocklatan 0.02%-0.005% Ophthalmic SolutionDrug
netarsudil and latanoprost 0.02%/0.005%
Latanoprost 0.005% Ophthalmic SolutionDrug
Latanoprost 0.005%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in mean diurnal intraocular pressure (IOP) from baselineTime frame: 3 months post-treatment initiation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eye Centers of Southeast Texas
Beaumont, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.